Artal Group S.A. — Q3 2025 13F-HR

← Artal Group S.A.

Q3 2025 · 13F-HR

Artal Group S.A.holdings as filed

Filed 2025-11-12 · accession 0001053906-25-000012

$758.2M

Reported value

Positions

2025-09-30

Period end

View analyzed profile →PRO

The Brief · Artal Group S.A. · Q3 2025

AI · grounded in 13F

Artal Group S.A. established a new position in Cava Group Inc CAVA valued at $574.4M. The fund also initiated a new stake in Lexicon Pharmaceuticals Inc LXRX worth $183.8M. These two holdings comprise the fund's total assets under management of $758.2M.

Holdings as filed

CUSIP	Ticker	Issuer	Value	% port.	Shares	Class	Voting
148929102	CAVA	Cava Group Inc	$574.4M	75.8%	9,507,990	Common	SOLE
528872302	LXRX	Lexicon Pharmaceuticals Inc	$183.8M	24.2%	136,180,481	Common	SOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.